Cargando…

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

Detalles Bibliográficos
Autores principales:	Palandri, Francesca, Gröpper, Stefanie, Loschi, Michael, Bellesso, Marcelo, Grosicki, Sebastian, Giraldo, Pilar, Harrison, Claire, Clevenger, Tracy, Stuart, Nikki, Qamoos, Hope, Vosganian, Gregory, Rothbaum, Wayne P., Verstovsek, Srdan, Vachhani, Pankit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428783/ http://dx.doi.org/10.1097/01.HS9.0000975544.01102.10

Ejemplares similares

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
por: Loschi, Michael, et al.
Publicado: (2023)

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
por: Mascarenhas, John, et al.
Publicado: (2023)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
por: Gulrajani, Michael, et al.
Publicado: (2023)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
por: Vachhani, Pankit, et al.
Publicado: (2023)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
por: Chary Nimmagadda, Subbaiah, et al.
Publicado: (2023)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
por: Watts, Justin M., et al.
Publicado: (2023)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL
por: Gerds, Aaron T., et al.
Publicado: (2023)

Collaboration Agreement KE2198/TE
por: European Organization for Nuclear Research, CERN, et al.
Publicado: (2013)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
por: Gupta, V., et al.
Publicado: (2022)

Amendment No.1 to Collaboration Agreement KE2198/TE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2013)

Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature
por: Vachhani, Pankit, et al.
Publicado: (2014)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
por: Ali, Haris, et al.
Publicado: (2023)

RuX: A Novel, Flexible, and Sensitive Mifepristone-Induced Transcriptional Regulation System
por: Meinzinger, Anne, et al.
Publicado: (2023)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Procedural analgesic interventions in China: a national survey of 2198 hospitals
por: Wang, Yafeng, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
por: Al-Ali, Haifa Kathrin, et al.
Publicado: (2023)

Comparative Insight into the Interfacial Phase Evolutions during Solution Treatment of Dissimilar Friction Stir Welded AA2198-AA7475 and AA2198-AA6013 Aluminum Sheets
por: Jandaghi, Mohammad Reza, et al.
Publicado: (2021)

How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes
por: Sharafeldin, Noha, et al.
Publicado: (2022)

Pion-Deuteron Coherent Scattering at 895 MeV/c
por: Bradamante, Franco, et al.
Publicado: (1968)

895. Prediction of Occurrence for Surgical Site Infection in Infected Surgeries
por: de Souza, Flávio Henrique Batista, et al.
Publicado: (2020)

POS-895 Post-COVID viral dermatoses and lupus patients
por: SAKAY, A., et al.
Publicado: (2022)

PReS-FINAL-2198: Insufficient efficacy of tocilizumab therapy in children with Castleman's disease
por: Kozlova, A, et al.
Publicado: (2013)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
por: Chen, Sunnia T., et al.
Publicado: (2022)

Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
por: Liu, Shuozi, et al.
Publicado: (2022)

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023)

Prospective analysis of 895 patients on a UK Genomics Review Board
por: Moore, David Allan, et al.
Publicado: (2019)

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases
por: Bosman, Ariadne, et al.
Publicado: (2022)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
por: Pandey, Manu R., et al.
Publicado: (2017)

2198. Increased Global Incidence and Altered Demographic Profile of Hepatitis Delta Virus (HDV)
por: Weller, Melodie, et al.
Publicado: (2018)

2198: Gender differences in the pharmacology of buprenorphine sublingual tablets in Hispanics/Latinos: An underrepresented population
por: Ivelisse Santiago, Darlene, et al.
Publicado: (2018)

2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
por: McDonell, Katherine, et al.
Publicado: (2018)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

2198. Assessing Strengths and Opportunities of Antibiotic Stewardship Programs in Philadelphia Skilled Nursing Facilities
por: Menanno, Mariah, et al.
Publicado: (2023)

An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples
por: Adam, Ishag, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ui7vuirjatabbtfon76v8nsp8